Cell Counting Kit-8 (CCK-8): Sensitive WST-8 Cell Viability Assay

Executive Summary: The Cell Counting Kit-8 (CCK-8) is a sensitive, water-soluble tetrazolium salt-based cell viability assay that quantitatively measures living cell numbers via WST-8 bioreduction (APExBIO, product page). It provides rapid, direct quantification of cell metabolic activity with higher sensitivity and lower toxicity than MTT or XTT assays (contrast article). CCK-8 is validated for diverse cell types and widely adopted in cancer, neurodegenerative, and cytotoxicity screening research (Li et al., 2025, DOI). The assay’s water-soluble formazan eliminates solubilization steps, enabling straightforward readout via microplate reader. Optimized protocols and minimal hands-on time make CCK-8 a preferred choice for high-throughput and reproducible in vitro viability assessment.

Biological Rationale

The quantification of viable cells is foundational in cell biology, toxicology, and drug discovery. Cell viability reflects metabolic competency, proliferation, and cytotoxicity response. Traditional colorimetric assays (e.g., MTT, XTT) are hampered by insoluble formazan formation, requiring post-assay solubilization steps and introducing variability. The Cell Counting Kit-8 (CCK-8) addresses these limitations by employing a water-soluble tetrazolium salt (WST-8), which is enzymatically reduced in live cells to generate a water-soluble formazan dye directly proportional to cell number (see prior review). This streamlines workflows and enhances reproducibility, especially in high-throughput settings. High sensitivity enables detection of subtle changes in proliferation or cytotoxicity, critical for applications in cancer research, neurodegenerative disease modeling, and compound screening (related).

Mechanism of Action of Cell Counting Kit-8 (CCK-8)

CCK-8 uses WST-8, a water-soluble tetrazolium salt, as its core detection reagent. In metabolically active (viable) cells, intracellular dehydrogenases—primarily mitochondrial enzymes—reduce WST-8 in the presence of an electron mediator to generate an orange formazan dye. The chemical reaction can be summarized as:

• WST-8 + NADH/NADPH → Water-soluble formazan (orange, λ_max ≈ 450 nm)

The amount of formazan produced is directly proportional to the number of viable cells, as only living cells possess active dehydrogenase systems. The assay is non-radioactive, and the formazan remains water-soluble, allowing for direct quantification in the culture medium without additional solubilization (APExBIO product page). This feature minimizes cytotoxicity and preserves sample integrity for downstream analyses. The reaction is typically complete within 1–4 hours at 37°C, and the absorbance is measured at 450 nm using a standard microplate reader.

Evidence & Benchmarks

• CCK-8 exhibits linearity between cell number and absorbance (λ=450 nm) across 500–50,000 cells/well in 96-well plates, enabling quantitative viability assessment (Li et al., 2025, DOI:10.1039/d5tb01441g).
• WST-8 produces a water-soluble formazan, removing the need for post-assay solubilization, thus reducing assay variability (Site Review).
• Compared to MTT, CCK-8 demonstrates improved sensitivity (detection limit ~100 cells/well), and faster reaction kinetics (1–2 h) under standard conditions (37°C, 5% CO₂) (Benchmark article).
• Enzymatic reduction of WST-8 is strongly correlated with mitochondrial dehydrogenase activity, a robust biomarker of metabolic cell viability (Li et al., 2025, DOI:10.1039/d5tb01441g).
• CCK-8 is validated for use in cancer, neurodegenerative, and drug toxicity studies, supporting reproducibility across mammalian cell lines (Application note).

Applications, Limits & Misconceptions

CCK-8 is broadly applied in:

• Cancer research: Quantifying proliferation and cytotoxicity in tumor cell lines (advanced AML application), extending previous work by demonstrating higher throughput and lower background than classical MTT.
• Neurodegenerative disease studies: Assessing neuronal viability in models of oxidative stress, supplementing mechanistic studies with quantitative endpoints.
• Drug screening: Evaluating compound cytotoxicity and metabolic activity with rapid, reproducible readout.
• Regenerative medicine and stem cell biology: Monitoring cell expansion or differentiation capacity in vitro.

Common Pitfalls or Misconceptions

• CCK-8 measures metabolic activity, not absolute cell number—altered metabolism (e.g., by mitochondria-targeted drugs) may bias results.
• Dead or severely damaged cells with residual dehydrogenase activity can produce low-level signal, potentially overestimating viability.
• Highly reducing culture media/components (ascorbate, phenol red) can interfere with WST-8 reduction—controls are critical.
• The assay is not suitable for non-adherent cells without optimization, as cell loss during washing/skipping may affect readout.
• CCK-8 cannot distinguish between cell cycle states or apoptosis vs. necrosis—complementary assays may be needed.

Workflow Integration & Parameters

CCK-8 (APExBIO K1018 kit) is compatible with most standard 96- and 384-well plate formats. A typical workflow includes:

1. Plate cells at desired density (e.g., 2,000–10,000 cells/well in 96-well plate).
2. Treat with compounds or conditions of interest; include appropriate controls.
3. Add 10 μL CCK-8 reagent per 100 μL medium per well.
4. Incubate 1–4 hours at 37°C, 5% CO₂.
5. Measure absorbance at 450 nm using a microplate reader.
6. Data analysis: Subtract background (medium + CCK-8, no cells) and normalize to control wells.

Minimal cytotoxicity allows for downstream molecular analysis of the same sample. The kit is shelf-stable at 2–8°C and does not require light protection. For troubleshooting and advanced protocol optimization, see related practical guides (workflow extension).

Conclusion & Outlook

The Cell Counting Kit-8 (CCK-8) represents a sensitive, robust, and user-friendly solution for cell viability and cytotoxicity measurement. Its WST-8 chemistry eliminates post-assay processing and provides superior reproducibility compared to legacy assays like MTT or XTT (CCK-8 product information). As research moves toward high-throughput, multiplexed, and quantitative approaches, CCK-8’s compatibility with automation and minimal interference positions it as a gold standard. Future development may integrate CCK-8 with real-time imaging and multi-omics platforms, further extending its impact in drug discovery and disease modeling. APExBIO continues to provide validated, high-quality CCK kits to meet evolving research needs.